Danaher Corporation (DHR)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$194.18+0.29%
Close 2026-07-07 · 1-day change
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading DHR? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DHR free→QuarterlyIQ Insights · DHR
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. Current price $194.18. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $194 DHR trades at 24× p/e, below its 35× p/e peer median, but our blended $197 fair value is roughly in line with the price. It's a high-confidence read. Analysts target $200–$249. Note: our $197 fair value sits below the entire analyst range ($200–$249). Not investment advice.
$200.00 – $249.00 (median $230.00) · 8 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 60% over what the business is worth with no growth; closing that gap needs roughly 9.3 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $7.14/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $230.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $65.54 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $52.68 | — | — | Hist. CAGR | high |
| graham number | 12M | $115.63 | — | — | TTM | high |
| Mgmt guidance | 12M | $298.48 | 35.3 | 8.45 | Mgmt | high |
| Peer P/FCF | 12M | $234.59 | 31.5 | 7.44 | TTM | high |
| Peer P/E | 12M | $281.88 | 35.3 | 7.98 | TTM | high |
| Peer P/S | 12M | $126.94 | 3.6 | 34.84 | TTM | high |
| PEG | 12M | $311.34 | 39.0 | 7.98 | TTM | high |
| residual income | 12M | $79.22 | — | — | TTM | high |
| Own P/E history | 12M | $196.30 | 24.6 | 7.98 | TTM | high |
| triangulated | 12M | $298.70 | 35.3 | 8.46 | Triangulated | high |
| Mgmt guidance | 3Y | $398.86 | 35.3 | 11.29 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $169.54 | 31.5 | 5.38 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $348.77 | 35.3 | 9.87 | Analyst | medium |
| Peer P/S | 3Y | $155.04 | 3.6 | 42.55 | guidance | medium |
| PEG | 3Y | $385.23 | 39.0 | 9.87 | Analyst | medium |
| Own P/E history | 3Y | $242.89 | 24.6 | 9.87 | Analyst | medium |
| Mgmt guidance | 5Y | $483.91 | 35.3 | 13.70 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $136.54 | 31.5 | 4.33 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $380.86 | 35.3 | 10.78 | Analyst | high |
| Peer P/S | 5Y | $169.31 | 3.6 | 46.47 | guidance | high |
| PEG | 5Y | $420.68 | 39.0 | 10.78 | Analyst | high |
| Own P/E history | 5Y | $265.24 | 24.6 | 10.78 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.